Pipeline
Four programmes. One architecture. One compounding discovery engine.
The same AI. The same functional screening. The same modular multispecific design — encoding different immune instructions across myeloma, solid tumours, autoimmune disease, and AML.
Since 2021, the same discovery infrastructure has produced CB-101 in myeloma, a solid-tumour programme with in vivo proof-of-concept complete, an autoimmune lead in optimisation, and an AML discovery programme — four programmes across three disease settings. One platform. One engine.
| Programme | Format | Development Stage |
|---|---|---|
| CB-101 Multiple Myeloma | OR-gated trispecific TCE | Discovery Lead Opt IND-enabling Phase I Phase II |
| CB-102 Solid Tumours | Multispecific | Discovery Lead Opt IND-enabling Phase I Phase II |
| CB-103 AML | Multispecific | Discovery Lead Opt IND-enabling Phase I Phase II |
| CB-201 Autoimmune | Multispecific, precision B-cell depletion | Discovery Lead Opt IND-enabling Phase I Phase II |
Stage and modality disclosed. Targets are not disclosed on this page.